PACBPacific Biosciences of California, Inc.
$2.30+64% 1Y
$2.30
$1.1152 weeks$2.88
The financials
Pacific Biosciences of California, Inc. by the numbers
Pacific Biosciences of California, Inc. (PACB) reported revenue of $39M in Q2 2026 (quarter ended Jun 30, 2026), down 1.9% from the same quarter a year earlier. That came with a gross margin of 32% and net loss of $45M. For the full year FY2025, revenue was $160M (+3.9% year on year) and net income −$546M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $39M | $40M | −1.9% |
| Gross profit | $13M | $15M | −14% |
| Operating income | −$45M | −$45M | n/a |
| Net income | −$45M | −$42M | n/a |
| Diluted EPS | −$0.14 | −$0.14 | n/a |